The market for amyotrophic lateral sclerosis (ALS) products across mature markets could reach $1.3 billion by 2029, up from $317 million in 2019, according to GlobalData.
Key opinion leaders interviewed by the industry analyst highlighted the critical unmet needs in the ALS space, such as early diagnosis, disease-modifying therapies (DMTs), and the identification of biomarkers.
KOLs surveyed by the firm emphasized that early diagnosis and DMT development are crucial for advancing ALS treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze